tiprankstipranks
FSD Pharma Trials Supplement for Alcohol Intoxication
Company Announcements

FSD Pharma Trials Supplement for Alcohol Intoxication

Fsd Pharma (TSE:HUGE) has released an update.

Pick the best stocks and maximize your portfolio:

FSD Pharma has partnered with ASPI to launch a clinical trial in the U.S. to evaluate the efficacy and safety of their dietary supplement, unbuzzd™, which aims to counteract alcohol intoxication. The METAL-2 trial will test the supplement’s ability to reverse alcohol effects against a placebo with thirty volunteers. This research aims to solidify FSD Pharma’s position as a frontrunner in addressing alcohol intoxication through innovative products.

For further insights into TSE:HUGE stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskQuantum BioPharma Debuts Ticker ‘QNTM’ After Rebrand
TheFlyOne new option listing and one option delisting on August 15th
TheFlyFDS Pharma trading halted, news pending
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App